Epidermal growth factor receptor (EGFR) is overexpressed in a variety of human malignancies， including pancreatic cancer， breast cancer， colon cancer， and non-small cell lung cancer. Overexpression of EGFR is a predictive marker of therapeutic response and several lines of evidence suggest that EGFR is an excellent target for tumor therapy. However， the effective antitumor capacity of EGFR-specific T cells against EGFR-overexpressing tumor cells has not been fully elucidated. In our previous study， we identified an anti-EGFR single-chain variable fragment (scFv) with specific and high affinity after screening by ribosome display. In this study， the anticancer potential of anti-EGFR scFv was invest... More
Epidermal growth factor receptor (EGFR) is overexpressed in a variety of human malignancies， including pancreatic cancer， breast cancer， colon cancer， and non-small cell lung cancer. Overexpression of EGFR is a predictive marker of therapeutic response and several lines of evidence suggest that EGFR is an excellent target for tumor therapy. However， the effective antitumor capacity of EGFR-specific T cells against EGFR-overexpressing tumor cells has not been fully elucidated. In our previous study， we identified an anti-EGFR single-chain variable fragment (scFv) with specific and high affinity after screening by ribosome display. In this study， the anticancer potential of anti-EGFR scFv was investigated on the basis of cell-targeted therapy. A chimeric antigen receptor (CAR) targeting EGFR was constructed and expressed on the cell membrane of T lymphocytes. These CAR-modified T cells demonstrated antitumor efficacy both in vitro and in vivo. In addition， the safety evaluation showed that CAR-modified lymphocytes have no or very minimal acute systemic toxicity. Taken together， our study provided the experimental basis for clinical application of genetically engineered lymphocytes; moreover， we also evaluate a new and interesting cell therapy protocol.
